What is Wedbush’s Estimate for APLS FY2024 Earnings?

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Wedbush boosted their FY2024 earnings estimates for shares of Apellis Pharmaceuticals in a research report issued on Thursday, January 23rd. Wedbush analyst L. Chico now expects that the company will post earnings per share of ($1.75) for the year, up from their previous forecast of ($1.77). The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.70) per share. Wedbush also issued estimates for Apellis Pharmaceuticals’ Q4 2024 earnings at ($0.44) EPS, Q1 2025 earnings at ($0.50) EPS, Q2 2025 earnings at ($0.47) EPS, Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.36) EPS, FY2025 earnings at ($1.75) EPS, FY2026 earnings at ($0.94) EPS, FY2027 earnings at $0.96 EPS, FY2028 earnings at $2.23 EPS and FY2029 earnings at $3.77 EPS.

A number of other equities analysts have also recently issued reports on APLS. Oppenheimer dropped their price target on shares of Apellis Pharmaceuticals from $65.00 to $40.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $26.00 target price on shares of Apellis Pharmaceuticals in a research note on Tuesday, January 21st. HC Wainwright reissued a “buy” rating and set a $57.00 price target on shares of Apellis Pharmaceuticals in a research report on Tuesday, January 14th. Scotiabank decreased their price objective on shares of Apellis Pharmaceuticals from $35.00 to $30.00 and set a “sector perform” rating for the company in a report on Wednesday, November 6th. Finally, Citigroup cut their target price on Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Eight investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Apellis Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $46.71.

Apellis Pharmaceuticals Trading Down 1.7 %

Apellis Pharmaceuticals stock opened at $29.28 on Monday. Apellis Pharmaceuticals has a 12 month low of $24.34 and a 12 month high of $71.90. The company has a market capitalization of $3.64 billion, a price-to-earnings ratio of -14.42 and a beta of 0.94. The business’s fifty day simple moving average is $32.16 and its two-hundred day simple moving average is $32.99. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The company had revenue of $196.83 million during the quarter, compared to the consensus estimate of $200.00 million. During the same period in the prior year, the firm earned ($1.17) earnings per share. The business’s revenue for the quarter was up 78.3% compared to the same quarter last year.

Insiders Place Their Bets

In related news, General Counsel David O. Watson sold 3,323 shares of the business’s stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $30.43, for a total transaction of $101,118.89. Following the completion of the transaction, the general counsel now directly owns 144,994 shares in the company, valued at approximately $4,412,167.42. The trade was a 2.24 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO James George Chopas sold 1,096 shares of the firm’s stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $30.43, for a total transaction of $33,351.28. Following the sale, the chief accounting officer now owns 48,138 shares in the company, valued at approximately $1,464,839.34. The trade was a 2.23 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 55,112 shares of company stock worth $1,655,767. Company insiders own 6.80% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of APLS. Amalgamated Bank boosted its stake in Apellis Pharmaceuticals by 5.4% in the second quarter. Amalgamated Bank now owns 6,995 shares of the company’s stock valued at $268,000 after acquiring an additional 359 shares in the last quarter. KBC Group NV increased its position in shares of Apellis Pharmaceuticals by 34.8% during the third quarter. KBC Group NV now owns 2,632 shares of the company’s stock worth $76,000 after purchasing an additional 679 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Apellis Pharmaceuticals by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock worth $130,000 after purchasing an additional 781 shares in the last quarter. Wolverine Asset Management LLC purchased a new position in Apellis Pharmaceuticals during the 3rd quarter worth $27,000. Finally, True Wealth Design LLC acquired a new position in Apellis Pharmaceuticals during the 3rd quarter valued at about $27,000. Institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).